Content area
Full Text
Cancer Diagnostics
Background: Sensitive monitoring of minimal residual disease may improve the treatment of neuroblastoma in children. To detect and monitor neuroblastoma cells in blood and bone marrow, we developed a quantitative method for the analysis of tyrosine hydroxylase mRNA.
Methods: We used real-time reverse transcription-PCR. The calibrator was constructed from a segment of tyrosine hydroxylase mRNA that included the target. Blood and bone marrow samples from 24 children with neuroblastoma and 1 child with ganglioneuroma were analyzed. Controls were blood samples from the cords of 40 babies, from 58 children 6 months to 15 years of age, and from 34 healthy adults, as well as from 12 children with other diseases.
Results: The detection limit was ~70 transcripts/mL. All 144 blood controls were below this limit. At diagnosis, blood tyrosine hydroxylase mRNA was higher in children with widespread disease (stage 4/4S; n = 6; range, 203-46 000 transcripts/mL) than in patients with localized disease (stages 1-3; n = 6; 583 transcripts/mL; P = 0.002). Bone marrow from all five children with localized disease had concentrations <72 transcripts/mL, whereas five of six stage 4 patients had increased concentrations (6000-8 000 000 transcripts/mL; P <0.05). In nine children in whom tyrosine hydroxylase mRNA was measured repeatedly, the results corresponded to the clinical course.
Conclusion: Quantitative analysis of tyrosine hydroxylase mRNA in blood and bone marrow is reliable and easy to perform and may be used for upfront staging, prognostic assessment, and treatment monitoring of neuroblastoma.
(C) 2003 American Association for Clinical Chemistry
Neuroblastoma, the most common solid malignant extracranial tumor in childhood, develops from sympathetic precursor cells of neural crest origin. The disease is predominantly found in young children and infants, and the tumor is characterized by clinical heterogeneity, ranging from slow-growing resectable tumors to disseminated forms with widespread metastases at diagnosis and a poor survival despite intensive multimodal therapy. A large majority of neuroblastomas produce catecholamines; the tumor cells thus express tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis (1).
Neuroblastoma patients are divided into five stages, 1-4 and 4S, according to the International Neuroblastoma Staging System. Despite multimodal therapy, children with metastatic stage 4 disease have a poor prognosis (2). Neuroblastoma cells frequently infiltrate bone marrow; therefore, evaluation of bone marrow...